Dare Bioscience (DARE) EBT Margin (2016 - 2026)
Dare Bioscience's (DARE) quarterly EBT Margin came in at 1582.53% in Q2 2026, down 1966207.0% on a YoY basis from N/an in Q2 2025, and down 1001.09% quarter-over-quarter from 143.72% in Q4 2025.
Powered by 
Analysis
Dare Bioscience (DARE) EBT Margin (2016 - 2026) Analysis & Trends
Dare Bioscience (DARE) has reported EBT Margin for 7 consecutive years, with 1582.53% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBT Margin fell 1966207.0% year-over-year to 1582.53%; the trailing twelve-month figure through Jun 2026 stood at 1001.35% (down 10526604.0% YoY), and the FY2025 full-year result was 1315.51%, up 23837669.0% from the prior year.
- EBT Margin fell to 1582.53% in Q2 2026 per DARE's latest filing, from 143.72% in the prior quarter.
- Across five years, EBT Margin topped out at 18079.54% in Q2 2025 and bottomed at 162340.76% in Q3 2025.
- Historically, EBT Margin has averaged 22220.34% across 5 years, with a median of 1211.09% in 2023.
- The widest YoY moves for EBT Margin: up 5087866 bps in 2025, down 15111208 bps in 2025.
- Over 5 years, EBT Margin stood at 3.84% in 2022, then plunged by 7543 bps to 286.05% in 2023, then soared by 3060 bps to 8465.75% in 2024, then plunged by 102 bps to 143.72% in 2025, then slumped by 1001 bps to 1582.53% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 1582.53%, 143.72%, and 162340.76% for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 4.84% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -2.67% |
| 10 | Dare Bioscience | 10.92 Mn | -1.70 Mn | -132,343.00 | -1,582.53% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,582.53% |
| Dec 31, 2025 | -143.72% |
| Sep 30, 2025 | -162,340.76% |
| Jun 30, 2025 | 18,079.54% |
| Mar 31, 2025 | -17,927.98% |
| Dec 31, 2024 | 8,465.75% |
| Sep 30, 2024 | -11,228.68% |
| Jun 30, 2024 | -32,799.12% |
| Mar 31, 2024 | -66,044.70% |
| Dec 31, 2023 | -286.05% |
| Sep 30, 2023 | -839.64% |
| Jun 30, 2022 | 3.84% |
| Jun 30, 2017 | -71.59% |
| Mar 31, 2017 | -83.26% |
| Dec 31, 2016 | -81.68% |